医学
蛋白尿
肾脏疾病
肾小球疾病
局灶节段性肾小球硬化
内科学
利格列汀
塔姆-霍斯法尔蛋白
肾功能
急性肾损伤
重症监护医学
肾
糖尿病
蛋白尿
内分泌学
2型糖尿病
作者
Jian Wen Samuel Lee-Boey,Jia‐Kai Tan,Zhan‐Foong Lim,Francesco Zaccardi,Kamlesh Khunti,Majid Ezzati,Edward W. Gregg,Lee‐Ling Lim
摘要
Obesity-related glomerulopathy (ORG) is an emerging complication of excess adiposity. Its incidence rises alongside the obesity pandemic. Up to 40% of individuals can be affected by ORG, irrespective of the status of glomerular filtration rate and albuminuria. ORG is a distinct histological diagnosis based on kidney biopsy, showing classical features of an enlarged glomerulus with and without focal segmental glomerulosclerosis in the perihilar region seen with all categories of obesity. About 10% of individuals with ORG may progress to end-stage kidney disease. The invasive nature of kidney biopsy highlights the need for non-invasive biomarkers for improved screening, diagnosis and risk prediction of ORG. These biomarkers may narrow the gaps in the management of ORG by improving: (1) screening, diagnosis and differentiation of ORG from non-ORG conditions; (2) risk prediction and stratification of individuals at risk of progression to end-stage kidney disease including the detection of trajectories of progression; (3) monitoring of treatment safety and effectiveness and (4) development of novel therapeutic targets. In the present review, we discussed the pathophysiology, emerging biomarkers (such as kidney injury molecule-1 [KIM-1], uromodulin, klotho, circulating microRNA-21 [miR-21]) and future treatment strategies (metabolic surgery, sodium-glucose cotransporter-2 inhibitors, incretin-based therapy and non-steroidal mineralocorticoid antagonists) of ORG.
科研通智能强力驱动
Strongly Powered by AbleSci AI